88 related articles for article (PubMed ID: 15225779)
1. Targeting 1alpha,25-dihydroxyvitamin D3 antiproliferative insensitivity in breast cancer cells by co-treatment with histone deacetylation inhibitors.
Banwell CM; O'Neill LP; Uskokovic MR; Campbell MJ
J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):245-9. PubMed ID: 15225779
[TBL] [Abstract][Full Text] [Related]
2. Altered nuclear receptor corepressor expression attenuates vitamin D receptor signaling in breast cancer cells.
Banwell CM; MacCartney DP; Guy M; Miles AE; Uskokovic MR; Mansi J; Stewart PM; O'Neill LP; Turner BM; Colston KW; Campbell MJ
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2004-13. PubMed ID: 16609009
[TBL] [Abstract][Full Text] [Related]
3. Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells.
Khanim FL; Gommersall LM; Wood VH; Smith KL; Montalvo L; O'Neill LP; Xu Y; Peehl DM; Stewart PM; Turner BM; Campbell MJ
Oncogene; 2004 Sep; 23(40):6712-25. PubMed ID: 15300237
[TBL] [Abstract][Full Text] [Related]
4. Antiproliferative signalling by 1,25(OH)2D3 in prostate and breast cancer is suppressed by a mechanism involving histone deacetylation.
Banwell CM; Singh R; Stewart PM; Uskokovic MR; Campbell MJ
Recent Results Cancer Res; 2003; 164():83-98. PubMed ID: 12899515
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic repression of transcription by the Vitamin D3 receptor in prostate cancer cells.
Gommersall LM; Khanim FL; Peehl DM; Doherty AH; Campbell MJ
J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):251-6. PubMed ID: 15225780
[TBL] [Abstract][Full Text] [Related]
6. Identification of VDR-responsive gene signatures in breast cancer cells.
Towsend K; Trevino V; Falciani F; Stewart PM; Hewison M; Campbell MJ
Oncology; 2006; 71(1-2):111-23. PubMed ID: 17377416
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of serum-stimulated mitogen activated protein kinase by 1alpha,25(OH)2-vitamin D3 in MCF-7 breast cancer cells.
Capiati DA; Rossi AM; Picotto G; Benassati S; Boland RL
J Cell Biochem; 2004 Oct; 93(2):384-97. PubMed ID: 15368364
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic corruption of VDR signalling in malignancy.
Abedin SA; Banwell CM; Colston KW; Carlberg C; Campbell MJ
Anticancer Res; 2006; 26(4A):2557-66. PubMed ID: 16886664
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of ER and VDR is not sufficient to make ER-negative MDA-MB231 breast cancer cells responsive to 1alpha-hydroxyvitamin D5.
Peng X; Jhaveri P; Hussain-Hakimjee EA; Mehta RG
Carcinogenesis; 2007 May; 28(5):1000-7. PubMed ID: 17130524
[TBL] [Abstract][Full Text] [Related]
10. Differential biological effects of 1,25-dihydroxyVitamin D3 on melanoma cell lines in vitro.
Seifert M; Rech M; Meineke V; Tilgen W; Reichrath J
J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):375-9. PubMed ID: 15225804
[TBL] [Abstract][Full Text] [Related]
11. Distinct HDACs regulate the transcriptional response of human cyclin-dependent kinase inhibitor genes to Trichostatin A and 1alpha,25-dihydroxyvitamin D3.
Malinen M; Saramäki A; Ropponen A; Degenhardt T; Väisänen S; Carlberg C
Nucleic Acids Res; 2008 Jan; 36(1):121-32. PubMed ID: 17999998
[TBL] [Abstract][Full Text] [Related]
12. MAPK inhibition by 1alpha,25(OH)2-Vitamin D3 in breast cancer cells. Evidence on the participation of the VDR and Src.
Rossi AM; Capiati DA; Picotto G; Benassati S; Boland RL
J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):287-90. PubMed ID: 15225787
[TBL] [Abstract][Full Text] [Related]
13. 1alpha,25-Dihydroxyvitamin D3-3beta-(2)-bromoacetate, an affinity labeling derivative of 1alpha,25-dihydroxyvitamin D3 displays strong antiproliferative and cytotoxic behavior in prostate cancer cells.
Swamy N; Persons KS; Chen TC; Ray R
J Cell Biochem; 2003 Aug; 89(5):909-16. PubMed ID: 12874825
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of corepressors in aggressive androgen-independent prostate cancer cells results in loss of 1alpha,25-dihydroxyvitamin D3 responsiveness.
Ting HJ; Bao BY; Reeder JE; Messing EM; Lee YF
Mol Cancer Res; 2007 Sep; 5(9):967-80. PubMed ID: 17855664
[TBL] [Abstract][Full Text] [Related]
15. Growth inhibition of HT-29 human colon cancer cells by analogues of 1,25-dihydroxyvitamin D3.
Shabahang M; Buras RR; Davoodi F; Schumaker LM; Nauta RJ; Uskokovic MR; Brenner RV; Evans SR
Cancer Res; 1994 Aug; 54(15):4057-64. PubMed ID: 8033137
[TBL] [Abstract][Full Text] [Related]
16. Cross-talk between vitamin D receptor (VDR)- and peroxisome proliferator-activated receptor (PPAR)-signaling in melanoma cells.
Sertznig P; Dunlop T; Seifert M; Tilgen W; Reichrath J
Anticancer Res; 2009 Sep; 29(9):3647-58. PubMed ID: 19667161
[TBL] [Abstract][Full Text] [Related]
17. Prostaglandin metabolizing enzymes in correlation with vitamin D receptor in benign and malignant breast cell lines.
Thill M; Fischer D; Becker S; Cordes T; Dittmer C; Diedrich K; Salehin D; Friedrich M
Anticancer Res; 2009 Sep; 29(9):3619-25. PubMed ID: 19667157
[TBL] [Abstract][Full Text] [Related]
18. Effects of Histone Deacetylase Inhibitor (HDACi); Trichostatin-A (TSA) on the expression of housekeeping genes.
Mogal A; Abdulkadir SA
Mol Cell Probes; 2006 Apr; 20(2):81-6. PubMed ID: 16326072
[TBL] [Abstract][Full Text] [Related]
19. Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 Dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A.
Rashid SF; Moore JS; Walker E; Driver PM; Engel J; Edwards CE; Brown G; Uskokovic MR; Campbell MJ
Oncogene; 2001 Apr; 20(15):1860-72. PubMed ID: 11313934
[TBL] [Abstract][Full Text] [Related]
20. Effects of the histone deacetylase inhibitor trichostatin A on nuclear texture and c-jun gene expression in drug-sensitive and drug-resistant human H69 lung carcinoma cells.
El-Khoury V; Gomez D; Liautaud-Roger F; Trussardi-Régnier A; Dufer J
Cytometry A; 2004 Dec; 62(2):109-17. PubMed ID: 15517561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
